Print ArticleAgilent Technologies Inc. (NYSE: A) today introduced the industry's first commercial mouse Comparative Genomic Hybridization (CGH) microarray. Designed and validated for genome-wide profiling of DNA copy number changes, the Agilent Mouse Genome CGH Microarray 44A offers a new venue and performance capability for studying genomic aberrations in cancer and other genetic diseases in this critical model organism.
"This technology is potentially transformative, as cross-species comparison can serve as a powerful biological filter for complex oncogenomic data from human cancers," said Lynda Chin, M.D., associate professor of dermatology at Dana-Farber Cancer Institute. "The availability of this microarray offers a new level of resolution and sensitivity in the genomic analyses of mouse tumors."
Dr. Chin's laboratory focuses on the molecular genetics of cancer genesis and progression, with particular emphasis on the development and characterization of genetically engineered mouse models of cancers that recapitulate key aspects of the human counterpart.
Agilent launched its breakthrough oligo aCGH platform in January 2005. The company recently introduced major platform enhancements that include HD-CGH custom microarrays for pinpointing chromosomal gains and losses associated with cancer and other genetic-based illnesses. Now the company is expanding its portfolio of model organism microarrays to make this powerful platform accessible for a wider range of scientific applications.
"We've taken extra measures to design a microarray that truly represents the coverage and performance needed to detect genomic gains and losses," said Mike Booth, general manager of Agilent's Genomics Business. "Along with human catalog and custom HD-CGH microarrays, it gives researchers access to the most robust and complete family of application-specific products."
The Mouse Genome CGH Microarray 44A provides comprehensive genome-wide coverage with an emphasis on the most commonly studied genomic regions and cancer-related genes. It consists of over 43,000 60-mer oligonucleotide probes, empirically validated in multiple model systems, that span coding and noncoding sequences with an average spatial resolution of 35 kb. Coupled with Agilent's optimized assay protocols, this microarray allows researchers to identify and locate genetic alterations in this major model organism with the highest resolution and precision.
This microarray joins the recently expanded Agilent oligo aCGH platform, which also includes reagents, hardware, software, and an improved assay protocol. Each experiment requires only nanogram levels of total genomic DNA without genome complexity reduction. Researchers can now perform comparative genomic analysis in human and mouse with a single, easy-to-use workflow.
Major applications include: identifying and characterizing genomic changes associated with oncogenesis and other human genetic diseases; identifying new oncogenes and tumor suppressor genes as potential therapy targets; exploring drug resistance mechanisms associated with genomic changes; and defining constitutional as well as acquired genetic changes.
More information about Agilent's oligo aCGH solution is available at www.agilent.com/chem/goCGH.
About Agilent in Genomics
Agilent is a leading provider of microarray-based, genomics research solutions with more than 500 customers worldwide. Agilent's end-to-end solution includes reagents for sample preparation and microarray processing; hardware for sample QC and high-throughput microarray scanning; 60-mer oligo microarrays on industry-standard 1" x 3" glass slides for gene expression; comparative genomic hybridization and chromatin immunoprecipitation applications; custom microarray design services; and industry-leading GeneSpring and Rosetta software products for data analysis.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 28,000 employees serve customers in more than 110 countries. Agilent had net revenue of $7.2 billion in fiscal year 2004. Information about Agilent is available on the Web at www.agilent.com.
Source : Agilent
Mail to a Friend
Link to this article
